CX3CL1 and neurodegenerative disease: Recently, overviews of the CX3CR1-CX3CL1 axis in neurodegenerative diseases (Subbarayan et al., 2022; Fu et al., 2025; Vida et al., 2025), drug and PET tracers targeting G protein-coupled receptors (GPCRs) (Pissarek, 2020; Sun et al., 2020; Wang et al., 2025) have been published.